Skip to content
Sexuality – Lifestyle
Author:
VANDA PHARMACEUTICALS INC
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis – A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
July 16, 2026
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
July 15, 2026
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
July 10, 2026
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
July 7, 2026
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
May 27, 2026
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
May 7, 2026
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
May 6, 2026
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 4, 2026
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 1, 2026
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026
1
2
Next Page
→